Soleno Therapeutics Inc. Feed

2025-04-23 13:00:00 Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET 72,27 USD | +1,22%

2025-04-14 13:00:00 Soleno Therapeutics Announces VYKAT(TM) XR Launch 70,00 USD | +4,12%

2025-03-26 22:15:58 Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome 48,97 USD | -2,16%

2025-01-29 22:05:00 Soleno Therapeutics to Participate in Upcoming February Investor Conferences 49,36 USD | +0,78%

2024-12-17 22:05:00 Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC 47,65 USD | -0,58%

2024-11-27 14:00:00 Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference 55,84 USD | -4,29%

2024-11-26 14:30:00 Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome 58,34 USD | +1,96%

2024-11-14 22:05:00 Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 54,08 USD | -2,87%

2024-10-28 13:00:00 Soleno Therapeutics to Participate in Upcoming November Investor Conferences 55,31 USD | +0,71%

2024-10-21 14:00:00 Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. 53,75 USD | -0,76%

2024-10-08 14:30:00 Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome 51,97 USD | +9,11%

2024-09-16 22:05:00 Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference 52,79 USD | -0,09%

2024-08-27 14:00:00 Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome 49,04 USD | +6,31%

2024-08-19 22:17:13 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 51,21 USD | +5,72%

2024-08-15 14:00:00 Soleno Therapeutics Announces Updates to its Board of Directors 50,46 USD | +3,23%

2024-06-28 14:00:00 Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome 40,80 USD | -2,28%

2024-06-24 23:18:01 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 40,08 USD | -2,60%

2024-05-22 22:05:00 Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 42,87 USD | -3,16%

2024-05-22 14:00:00 Soleno Therapeutics to Participate in Upcoming Investor Conferences 42,87 USD | -3,16%

2024-05-15 14:00:00 Soleno Therapeutics Stands with the Prader-Willi Syndrome Community 45,21 USD | +3,93%

2024-05-03 04:32:12 Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock 45,12 USD | -8,35%

2024-05-02 22:01:37 Soleno Therapeutics Announces Proposed Public Offering of Common Stock 49,23 USD | +3,55%

2024-04-30 14:00:00 Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome 44,66 USD | -1,91%

2024-04-29 14:00:00 Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) 45,53 USD | +20,16%

2024-04-19 22:05:00 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 37,50 USD | +0,94%

2024-03-08 22:05:00 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 44,88 USD | -0,14%

2024-03-06 22:05:00 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results 46,38 USD | +2,16%

2024-02-22 14:00:00 Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference 48,61 USD | 0,00%

2024-01-29 22:05:00 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 47,99 USD | +2,98%

2024-01-24 14:00:00 Soleno Therapeutics Strengthens Leadership Team with Key Appointments 46,31 USD | -3,66%

2024-01-05 14:00:00 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 37,15 USD | +1,23%

2023-11-10 22:05:00 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 22,00 USD | -0,63%

2023-10-05 00:16:26 Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium 23,81 USD | -6,15%

2023-10-04 22:05:00 Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium 25,37 USD | -0,74%

2023-10-02 22:05:40 Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares 26,48 USD | -10,27%

2023-09-28 14:30:00 Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants 27,59 USD | +33,48%

2023-09-27 22:01:01 Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants 20,67 USD | -22,87%

2023-09-25 14:00:00 Soleno Therapeutics to Present at the Cantor Global Healthcare Conference 4,43 USD | +3,50%

2023-05-09 22:05:00 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results 4,32 USD | +2,86%

2023-03-28 14:00:00 Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days 2,30 USD | -2,95%

2023-03-21 21:05:00 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results 2,14 USD | +5,94%

2023-03-07 14:00:00 Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference 2,33 USD | +3,33%

2023-01-26 14:00:00 Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome 2,59 USD | +7,47%

2022-12-19 14:00:00 Soleno Therapeutics Announces Financing Commitment for up to $60 Million 1,85 USD | +103,86%

2022-11-09 22:05:00 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results 0,92 USD | -4,17%

2022-10-03 14:00:00 Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome 1,74 USD | +4,19%

2022-08-10 22:05:00 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results 0,18 USD | +2,65%

2022-07-11 22:05:00 Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference 0,19 USD | -11,41%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Soleno Therapeutics Inc.

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden